Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Capricor's Duchenne therapy has new life after FDA grants 3-month extension

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

The FDA has granted a three-month extension to Capricor Therapeutics for its Duchenne muscular dystrophy therapy deramcicel to review additional data and consider a refined indication, with a new target action date set for November 22, 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 14 Aug 2026 and 24 Aug 2026.

◆ ◆ The Wire takeaway

FDA's deadline extension opens a narrow window for you to strengthen clinical evidence and refine drug positioning for Duchenne muscular dystrophy therapy. Your near-term moves can reset market expectations and investor confidence ahead of approval.

◆ Coverage

4 sources · first reported 14 Aug 2026 · latest 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdadrug-approvalbiotechmuscular-dystrophyregulatory-extension